Statement of Changes in Beneficial Ownership (4)
18 6월 2021 - 6:16AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Srivastava Sapna |
2. Issuer Name and Ticker or Trading Symbol
SQZ Biotechnologies Co
[
SQZ
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
200 ARSENAL YARDS BLVD, SUITE 210 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/15/2021 |
(Street)
WATERTOWN, MA 02472
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option | $13.57 | 6/15/2021 | | A | | 10500 | | (1) | 6/14/2031 | Common Stock | 10500 | $0.00 | 10500 | D | |
Explanation of Responses: |
(1) | The option vests and becomes exercisable on the earlier of (i) June 15, 2022 or (ii) the day immediately prior to the date of the Issuer's next
annual meeting of stockholders following the date of grant, in each case subject to the Reporting Person's continued service on the Board. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Srivastava Sapna 200 ARSENAL YARDS BLVD, SUITE 210 WATERTOWN, MA 02472 | X |
|
|
|
Signatures
|
/s/ Lawrence Knopf, Attorney-in-Fact for Sapna Srivastava | | 6/17/2021 |
**Signature of Reporting Person | Date |
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024